Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Roche v. Organon Teknika

This article was originally published in The Gray Sheet

Executive Summary

Roche v. Organon Teknika: Organon Teknika's NASBA gene amplification technology used in two HIV tests available in Europe does not infringe Roche's European patent for polymerase chain reaction amplification technology, according to a Dec. 14 ruling by the President of the District Court in The Hague, the Netherlands. Rejecting Roche's request for an injunction of NASBA sales ("The Gray Sheet" Sept. 11, In Brief), the court stipulates that Roche must publicly announce the contents of the judgment and refrain from disseminating "further misleading information on the alleged infringement," Teknika says. Teknika adds that it has initiated pre-emptive legal action in the UK, France and Germany "to obtain declarations of non-infringement and is preparing such action in other countries." Roche says it will review the district court's findings before deciding whether it will appeal...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT005208

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel